OPKO Health (OPK)
(Delayed Data from NSDQ)
$0.87 USD
-0.03 (-3.27%)
Updated Mar 18, 2024 04:00 PM ET
After-Market: $0.88 +0.01 (1.68%) 7:58 PM ET
4-Sell of 5 4
C Value D Growth B Momentum D VGM
Price, Consensus and EPS Surprise
OPK 0.87 -0.03(-3.27%)
Will OPK be a Portfolio Killer in March?
Zacks Investment Research is releasing its prediction for OPK based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for OPK
OPKO Health's (OPK) Q4 Earnings Match Estimates, Revenues Top
OPKO Health (OPK) Reports Q4 Earnings: What Key Metrics Have to Say
OPK: What are Zacks experts saying now?
Zacks Private Portfolio Services
OPKO Health (OPK) Reports Q4 Loss, Tops Revenue Estimates
Gear Up for OPKO Health (OPK) Q4 Earnings: Wall Street Estimates for Key Metrics
IQVIA Holdings (IQV) Surpasses Q4 Earnings and Revenue Estimates
Other News for OPK
What's Driving Twist Bioscience Corp's Surprising 44% Stock Rally?
AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the Treatment and Prevention of HIV
Opko Health's ModeX presents results from Phase 1 study of SAR441236
Wall Street Analysts Are Bullish on Top Healthcare Picks
Immunic And 2 Other Stocks Under $2 Insiders Are Buying